Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Fred Verzijlbergen"'
Autor:
Jorinde Janssen, Walter Noordzij, Ton Velleman, Igle Jan de Jong, Johannes A. Langendijk, J. Fred Verzijlbergen, Gilles N. Stormezand, Shafak Aluwini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background/objectives: Accurate and uniform interpretation and reporting of metastatic prostate cancer (PCa) lesions on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) are indispensable. 18 F-PSMA-1
Externí odkaz:
https://doaj.org/article/2e2777181d9f4dfebbd7dc38dade61c0
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati
Externí odkaz:
https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79
Autor:
James Nagarajah, J. Alfred Witjes, Martin Gotthardt, Jelle O. Barentsz, Sandra Heskamp, Jean-Paul A. van Basten, Diederik M. Somford, Robert J. Smeenk, Linda G.W. Kerkmeijer, Niven Mehra, Winald R. Gerritsen, J. Fred Verzijlbergen, Tom W.J. Scheenen, Annemarie Eek, Melline G.M. Schilham, Maike J.M. Uijen, Patrik Zámecnik, Mark W. Konijnenberg, J.P. Michiel Sedelaar, Marcel J.R. Janssen, Inge M. van Oort, Constantijn H.J. Muselaers, Steffie M.B. Peters, Bastiaan M. Privé
Purpose:[177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee5227f2482c2e8c0f3bed1c1ab3d53
https://doi.org/10.1158/1078-0432.c.6530696.v1
https://doi.org/10.1158/1078-0432.c.6530696.v1
Autor:
James Nagarajah, J. Alfred Witjes, Martin Gotthardt, Jelle O. Barentsz, Sandra Heskamp, Jean-Paul A. van Basten, Diederik M. Somford, Robert J. Smeenk, Linda G.W. Kerkmeijer, Niven Mehra, Winald R. Gerritsen, J. Fred Verzijlbergen, Tom W.J. Scheenen, Annemarie Eek, Melline G.M. Schilham, Maike J.M. Uijen, Patrik Zámecnik, Mark W. Konijnenberg, J.P. Michiel Sedelaar, Marcel J.R. Janssen, Inge M. van Oort, Constantijn H.J. Muselaers, Steffie M.B. Peters, Bastiaan M. Privé
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5752047a06c3325540f120e571753c90
https://doi.org/10.1158/1078-0432.22481447
https://doi.org/10.1158/1078-0432.22481447
Autor:
Martin Gotthardt, J. Fred Verzijlbergen, Jean-Paul A. van Basten, Melline G.M. Schilham, James Nagarajah, Robert Jan Smeenk, Sandra Heskamp, J. Alfred Witjes, Steffie M. B. Peters, Tom W. J. Scheenen, Marcel J.R. Janssen, Inge M. van Oort, Maike J. M. Uijen, Jelle O. Barentsz, Niven Mehra, Michiel Sedelaar, Bastiaan M. Privé, Diederik M. Somford, Constantijn H.J. Muselaers, Annemarie Eek, Winald R. Gerritsen, Linda G W Kerkmeijer, Mark Konijnenberg, Patrik Zamecnik
Publikováno v:
Clinical Cancer Research, 27, 13, pp. 3595-3601
Clinical Cancer Research, 27, 3595-3601
Clinical Cancer Research, 27(13), 3595-3601. American Association for Cancer Research Inc.
Clinical Cancer Research, 27, 3595-3601
Clinical Cancer Research, 27(13), 3595-3601. American Association for Cancer Research Inc.
Purpose: [177Lu]Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1417fbe66740f01d576b0be4f529f08
https://doi.org/10.1158/1078-0432.CCR-20-4298
https://doi.org/10.1158/1078-0432.CCR-20-4298
Autor:
Willemijn A. M. van Gemert, Andries M. Bergman, Constantijn H.J. Muselaers, Henk G. van der Poel, Walter Noordzij, André N. Vis, Patrik Zamecnik, Bastiaan M. Privé, Harm Westdorp, Inge M. van Oort, Michel de Groot, James Nagarajah, Martin Gotthardt, Marianne A. Jonker, Winald R. Gerritsen, Daniela E. Oprea-Lager, Niven Mehra, Wouter V. Vogel, Marcel J.R. Janssen, Jelle O. Barentsz, J. Alfred Witjes, J. Fred Verzijlbergen, Tom W. J. Scheenen
Publikováno v:
Trials, 22, 1
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd678fcc14ec0890e40cb2bebbcdb4d3
http://www.scopus.com/inward/record.url?scp=85118722359&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85118722359&partnerID=8YFLogxK
Autor:
Berthold A. Nock, J. Fred Verzijlbergen, Ingrid L. Bakker, Simone U. Dalm, Theodosia Maina, Ivo G. Schoots, Wytske M. van Weerden, Alida Froberg, Geert J.L.H. van Leenders, Mark Konijnenberg, Erik de Blois, Martijn B. Busstra, Marion de Jong
Publikováno v:
Journal of Nuclear Medicine, 62(11). Society of Nuclear Medicine and Molecular Imaging
The gastrin releasing peptide receptor (GRPr) is overexpressed in prostate cancer (PCa) cells, making it an excellent tool for targeted imaging. The gallium-68 labeled GRPr antagonist SB3 (68Ga-SB3) has shown excellent results in (pre)clinical studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820c46e4863ced4b7c2e6925b93507ae
https://doi.org/10.2967/jnumed.120.258814
https://doi.org/10.2967/jnumed.120.258814
Autor:
Niven Mehra, Inge M. van Oort, Constantijn H.J. Muselaers, Michiel Sedelaar, Fred Verzijlbergen, Peter F.A. Mulders, James Nagarajah, J. Alfred Witjes, Melline G.M. Schilham, Patrik Zamecnik, Bas Israël, Bastiaan M. Privé, Marcel J.R. Janssen, Jelle O. Barentsz, Martin Gotthardt
Publikováno v:
Prostate Cancer and Prostatic Diseases, 24, 2, pp. 423-430
Prostate Cancer and Prostatic Diseases, 24, 423-430
Prostate Cancer and Prostatic Diseases, 24, 423-430
Item does not contain fulltext BACKGROUND: PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa). While there are several PSMA ligands available, F-18-PSMA-1007 is particularly of interest as it is not renally excreted and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23cdba8210bc849c575d7222b1342470
https://repository.ubn.ru.nl/handle/2066/235004
https://repository.ubn.ru.nl/handle/2066/235004
Autor:
Ingrid L, Bakker, Alida C, Fröberg, Martijn B, Busstra, J Fred, Verzijlbergen, Mark, Konijnenberg, Geert J L H, van Leenders, Ivo G, Schoots, Erik, de Blois, Wytske M, van Weerden, Simone U, Dalm, Theodosia, Maina, Berthold A, Nock, Marion, de Jong
Publikováno v:
J Nucl Med
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer (PCa) cells, making it an excellent tool for targeted imaging. The (68)Ga-labeled GRPr antagonist SB3 has shown excellent results in preclinical and clinical studies an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::11094d54e7e7b54e9e3938d2203f89fc
https://pubmed.ncbi.nlm.nih.gov/33789933
https://pubmed.ncbi.nlm.nih.gov/33789933